Novo Ventures Remains Bullish After ‘Very Active’ Year
VC Playbook: An Interview With Naveed Siddiqi
In this latest installment of VC playbook, In Vivo speaks to Naveed Siddiqi, senior partner at Novo Ventures. He discusses the group’s strategy, the European investment outlook for life sciences and how COVID-19 has permanently shifted perceptions of the biopharma industry.
You may also be interested in...
In this latest installment of the VC Playbook series, In Vivo sits down with SV Health Investors’s Houman Ashrafian. The managing partner outlines the group’s investment philosophy, today’s skill set for VC success, and expectations for the future of Britain’s biotech industry post-Brexit and post-pandemic.
A selection of articles you might have missed from April 2021, including exclusive interviews with industry leaders and a deeper dive into drug development and R&D.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.